Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

chronic breathlessness

  • Home
  • chronic breathlessness
Morphine Does Not Relieve Chronic Breathlessness: The MABEL Trial Finds No Benefit and Signals More Harms
Posted innews Respiratory

Morphine Does Not Relieve Chronic Breathlessness: The MABEL Trial Finds No Benefit and Signals More Harms

Posted by MedXY By MedXY 11/24/2025
A UK multicentre randomized placebo‑controlled trial (MABEL) showed no improvement in worst breathlessness with low‑dose oral morphine versus placebo at 28 days, with more adverse events and withdrawals in the morphine arm.
Read More
  • EndoBarrier Duodenal-Jejunal Bypass Liner: A Novel Endoscopic Adjunct for Improved Glycemic Control and Weight Loss in Type 2 Diabetes with Obesity
  • Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma
  • Severe Lead Poisoning During Pregnancy: Insights from a 19-Year NYC Observational Study
  • Unraveling Fibroblast Diversity in Vaginal Wall Prolapse: Insights from Single-Nucleus Transcriptomics
  • Reclassifying Pediatric NAFLD: Insights from the Steatotic Liver Disease Framework in a Multicenter NASH CRN Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in